Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Joan Wildenhain

Nurse Practitioner Cranston, RI Nurse Practitioner

NPI 1720073455 CMS profile 1010314

725 Reservoir Ave, Suite 101, Cranston, RI 02910

Open in the dashboard

General payments

$392

4 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joan Wildenhain of Cranston, RI is reported in the CMS Open Payments database as having received $392 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $159 2
2024 General $233 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joan Wildenhain
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Joan Wildenhain were reported at $159. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Joan Wildenhain Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $233 $173 $55–$556 $164
2025 $159 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Radius Health, Inc. $201 2 payments
  2. Amgen Inc. $191 2 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $392 4 payments
Products named General payments · program years 2024–2025
  1. Tymlos $201 2 payments
  2. EVENITY $191 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

967

Median for Nurse Practitioner: 389

Drug cost

$636,226

Median for Nurse Practitioner: $21,885

Branded share of claims

34%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prolia Denosumab Brand 199 $332,948
Evenity (2 Syringes) Romosozumab-Aqqg Brand 49 $117,627
Tymlos Abaloparatide Brand 35 $89,909
Forteo Teriparatide Brand 15 $60,010
Teriparatide Generic 13 $31,762
Celecoxib Generic 128 $1,821
Methylprednisolone Generic 82 $640
Ultra-Fine Mini Pen Needle Pen Needle, Diabetic Brand 31 $535
Meloxicam Generic 149 $243
Oxycodone Hcl Generic 47 $202

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$252,970

Of which drugs: $190,848

Medicare patients

523

Average age 74

Services billed

12,692

398 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Osteoporosis 59%
Ischemic heart disease 27%
Depression 27%
Diabetes 21%
Chronic kidney disease 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 89 9,360 $190,464
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 1,840 $190
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 200 $136
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 41 236 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $125
$125 49 —
Tymlos
  • Radius Health, Inc. $108
$108 35 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record